AerICU®

Consider the Aerogen AerICU® portfolio for your Intensive Care Unit (ICU)

Aerosol drug delivery is a widely used therapeutic strategy in the ICU1

Given the complexities of treating the critically ill patient, appropriate device choice is important, with many factors and challenges to consider.


Fugitive emissions are an important concern

The need to open a ventilator circuit to administer aerosolised medication is considered a potential risk factor for the release of fugitive aerosols.†2-4

Clinical and scientific societies around the world recommend the use of closed-circuit nebulisers for the management of patients with COVID-19 requiring aerosol drug delivery.4-10

Your chosen device should work across multiple respiratory and ventilatory support setups

To avoid disruption to oxygen delivery and ventilation, it is preferable to administer medical aerosols in-line via the respiratory support setup, such as high-flow, non-invasive ventilation and invasive mechanical ventilation.1

Several factors can impact aerosol drug delivery

These include “patient characteristics, breathing parameters, the severity of airway disease, the characteristics of aerosol devices, their integration into respiratory support devices and the interface of these devices to patients, their ease of use, and patient comfort.”1

Aerosol therapy in adult critically ill patients: a consensus statement, 20231

The AerICU portfolio addresses many of the challenges  associated with aerosol drug delivery in the ICU

Aerogen is a closed-circuit aerosol drug delivery system2,11

Invasive mechanical ventilation, Aerogen closed-circuit aerosol drug delivery system


With Aerogen, in-line aerosol drug delivery eliminates the need to open the circuit when administering medication. 2,11 

With a pMDI or jet nebuliser, it is necessary to open the respiratory circuit to deliver aerosolised medicine.12

In studies, the use of Aerogen for aerosol drug delivery was associated with lower fugitive aerosol emissions versus jet nebulisers during invasive mechanical ventilation,‡2 high-flow§13 and when self-ventilating.¶14,‖15

Workflow 2,11

Equipment required to supply compressed gas for jet nebulisers limits their portability.16,17

Using a continuous jet nebuliser in ventilated patients, with the need for added flow, affects tidal volume and FiO2 (fraction of inspired oxygen) and is not recommended for aerosol delivery in this setting.1

With Aerogen:

  • In-line aerosol drug delivery11
  • No added flow required11
  • Portable11
  • 28-days intermittent or 7-days continuous use11
  • One system throughout a patient’s respiratory journey (IMV, NIV, HF, self-ventilating [SV]),11 supporting continuity of care

The AerICU portfolio from Aerogen

Aerogen Solo

Aerogen® Solo

Aerogen® Solo is a vibrating mesh nebuliser intended for physician-prescribed medications for inhalation, which are approved for use with a general-purpose nebuliser.11

  • Quick and easy to set up11
  • Virtually silent11,18
  • Single patient use11
  • No added flow11
  • Powered by Aerogen Pro-X Controller11 or Aerogen USB Controller19

Discover more

Aerogen® Ultra

A handheld device used in conjunction with the Aerogen Solo to deliver inhalation treatment either during exacerbations or post-ventilation.20

Discover more

Aerogen Ultra

Aerogen® Pro-X Controller

The Aerogen Pro-X Controller® portable power source, with 30-minute and continuous modes, has been developed to facilitate aerosol medication delivery throughout the hospital.11

Discover more

Aerogen® USB Controller

A portable power source that can be operated from the USB connection and USB ports on ventilators and other medical equipment (not available in the US).19

Discover more

To learn more:

Download the AerICU brochure

Enquiries

The Aerogen team and our representatives are available globally to answer your questions, provide an online demonstration and place orders

How can we help

†The study by Joyce et al was performed in an in-vitro model of mechanical ventilation. ‡Defined as median (interquartile range) particulate number concentration during simulated drug refill in an in vitro model of invasive mechanical ventilation; between-group difference, 0/cm-3 (0.1–1.6) vs 710/cm-3(265–1211); P=0.032. §Defined as fugitive aerosol concentrations versus baseline with Aerogen via Airvo 2 (high-flow) versus jet nebuliser with mouthpiece of facemask at particles of 1.0–3.0 μm (all P<0.05); study performed in healthy subjects.Defined as mean aerosol concentrations at a distance of 0.8 m and 2.2 m over 30 minutes; in-vitro model of a self-ventilating adult. ‖Defined as fugitive aerosol concentrations with jet nebuliser vs Aerogen with a mask at particle sizes of 1.0–5 μm and with a mouthpiece at particle sizes of 0.5–3 μm (all P<0.05); study performed in healthy subjects.

  1. Li J, Liu K, Lyu S, et al. Ann Intensive Care. 2023;13(1):63. 2023;13(1):63. 
  2. Joyce M, McGrath JA, Mac Giolla Eain M, et al. Pharmaceutics. 2021;13(2):199. 
  3. O’Toole C, Joyce M, McGrath JA, et al. Ann Transl Med. 2021;9(7):592. 
  4. Fink JB, Ehrmann S, Li J, et al. J Aerosol Med Pulm Drug Deliv. 2020;33(6):300-304. 
  5. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: Global strategy for prevention, diagnosis and management of COPD, 2023. Available at: www.goldcopd.org/2023-gold-report-2/. Accessed: July 2024. 
  6. American Association for Respiratory Care SARS CoV-2 Guidance Document. Available at https://www.aarc.org/wp-content/uploads/2020/03/guidance-document-SARS-COVID19.pdf. Accessed: July 2024. 
  7. Cinesi Gómez C, Peñuelas Rodríguez Ó, Luján Torné M, et al. Med Intensiva (Engl Ed). 2020;44(7):429-438. 
  8. Respiratory care committee of Chinese Thoracic Society. Zhonghua Jie He He Hu Xi Za Zhi. 2020;17(0):E020. 
  9. Kumar S, Mehta S, Sarangdhar N, et al. Expert Rev Respir Med. 2021;15(4):519-535. 
  10. Swarnakar R, Gupta NM, Halder I, et al. Lung India. 2021;38(Supplement):S86-S91. 
  11. 30-354 Rev U Aerogen Solo System Instruction Manual. 
  12. Mac Giolla Eain M, et al. Drug Deliv. 2021;28(1):1496-1500. 
  13. Li J, Alolaiwat A, J Harnois L, Fink JB, Dhand R. Respir Care. 2022;67(4):404-414. 
  14. McGrath JA, O’Sullivan A, Bennett G, et al. Pharmaceutics. 2019;11(2):75. 
  15. Harnois LJ, Alolaiwat AA, Jing G, et al. Respir Care. 2022;67(4):394-403. 
  16. Gardenhire DS, Nozart L, Hinski S. A Guide to Aerosol Delivery Devices for Respiratory Therapists, 5th Edition.American Association for Respiratory Care, 2023. 
  17. Ari A. Eurasian J Pulmonol 2014;16:1-7. 
  18. Royal National Institute for Deaf People (RNID). How loud is too loud? https://rnid.org.uk/information-and-support/ear-health/protect-your-hearing/how-loud-is-too-loud/. Accessed: July 2024. 19. 30-763 Rev H Aerogen USB Controller System Instruction Manual. 20. 30-1487 Rev A Aerogen Ultra Instruction Manual.

GL-3344-1-EN Copyright © 2025 Aerogen Ltd. All rights reserved. AerICU, Aerogen, Aerogen Go, Aerogen Solo, Aerogen Ultra, Go, The WheeZees and Vibronic are trademarks or registered trademarks of Aerogen Ltd or its affiliates